Economics of drug development and provision
- Introduction: Economics of drug development and provision
- Life and medicines: price and value
- Appraising cancer drugs at the National Institute for Health and Clinical Excellence
- The challenge for the pharmaceutical industry in the 21st century: discovery, development and access to medicines in a distrustful environment
- Title to be confirmed
- First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC-Chemokine Ligand 2 (CCL2/MCP-1) in patients with advanced solid tumours
- Identification of a human antibody 3.19.3 that inhibits ANG-2 function leading to significant anti-tumour activity, both alone and in combination with VEGF inhibitors, in a panel of tumour xenograft models
- Novel anticancer drug combinations exploiting arginine depletion with ADI-PEG 20 in the treatment of ASS1-negative malignant mesothelioma
